About: Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations
Creator	Fagiolini, Andrea Barbui, Corrado Correll, Christoph Gastaldon, Chiara Ostuzzi, Giovanni Papola, Davide Stubbs, Brendon Taylor, David Thornicroft, Graham Amaddeo, Francesco Bertolini, Federico Cuomo, Alessandro Emsley, Robin Hiemke, Christoph Imperadore, Giuseppe Kishimoto, Taishiro Michencigh, Giulia Nosé, Michela Purgato, Marianna Schoretsanitis, Georgios Serdar, Dursun Ward, Philip
Source	Medline; PMC
abstract	BACKGROUND: The novel coronavirus pandemic calls for a rapid adaptation of conventional medical practices to meet the evolving needs of such vulnerable patients. People with coronavirus disease (COVID-19) may frequently require treatment with psychotropic medications, but are at the same time at higher risk for safety issues because of the complex underlying medical condition and the potential interaction with medical treatments. METHODS: In order to produce evidence-based practical recommendations on the optimal management of psychotropic medications in people with COVID-19, an international, multi-disciplinary working group was established. The methodology of the WHO Rapid Advice Guidelines in the context of a public health emergency and the principles of the AGREE statement were followed. Available evidence informing on the risk of respiratory, cardiovascular, infective, hemostatic, and consciousness alterations related to the use of psychotropic medications, and drug–drug interactions between psychotropic and medical treatments used in people with COVID-19, was reviewed and discussed by the working group. RESULTS: All classes of psychotropic medications showed potentially relevant safety risks for people with COVID-19. A set of practical recommendations was drawn in order to inform frontline clinicians on the assessment of the anticipated risk of psychotropic-related unfavorable events, and the possible actions to take in order to effectively manage this risk, such as when it is appropriate to avoid, withdraw, switch, or adjust the dose of the medication. CONCLUSIONS: The present evidence-based recommendations will improve the quality of psychiatric care in people with COVID-19, allowing an appropriate management of the medical condition without worsening the psychiatric condition and vice versa.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1186/s12916-020-01685-9
bibo:pmid	32664944
has license	cc-by
sha1sum (hex)	33e52388805d4a902c117dee34a348c076c704eb
schema:url	https://doi.org/10.1186/s12916-020-01685-9
resource representing a document's title	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations
has PubMed Central identifier	PMC7360478
has PubMed identifier	32664944
schema:publication	BMC Med
resource representing a document's body	covid:33e52388805d4a902c117dee34a348c076c704eb#body_text
is schema:about of	named entity 'evolving' named entity 'frequently' named entity 'medical' named entity 'higher risk' named entity 'medical treatments' named entity 'off-label' named entity 'risk factors' named entity 'Antipsychotic medications' named entity 'mood stabilizers' named entity 'dementia' named entity 'comorbidities' named entity 'psychopharmacological' named entity 'respiratory distress' named entity 'sample size' named entity 'psychotropic medications' named entity 'hypokalemia' named entity 'medical conditions' named entity 'stroke' named entity 'systematic reviews' named entity 'COPD' named entity 'thoracic' named entity 'respiratory distress' named entity 'QTc prolongation' named entity 'COPD' named entity 'carbamazepine' named entity 'pharmacodynamic' named entity 'extrapyramidal symptoms' named entity 'psychotropic medications' named entity 'Cochrane Database of Systematic Reviews' named entity 'observational studies' named entity 'COVID' named entity 'psychiatric condition' named entity 'respiratory distress' named entity 'confidence interval' named entity 'psychomotor agitation' named entity 'pharmacological' named entity 'antidepressants' named entity 'GRADE' named entity 'prophylaxis' named entity 'antipsychotics' named entity 'respiratory depression' named entity 'medical drugs' named entity 'kidney injury' named entity 'randomized trials' named entity 'clozapine' named entity 'barbiturates' named entity 'observational studies' named entity 'cardiac events' named entity 'drug-drug interactions' named entity 'study designs' named entity 'disseminated intravascular coagulation' named entity 'mood stabilizers' named entity 'QTc prolongation' named entity 'COVID-19' named entity 'comorbid' named entity 'sedative' named entity 'PubMed' named entity 'COVID' named entity 'psychiatric condition' named entity 'risk factors'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software